Definium Therapeutics (DFTX) Total Liabilities (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Total Liabilities data on file, last reported at $122.4 million in Q1 2026.

• Quarterly Total Liabilities rose 133.15% year-over-year to $122.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.4 million (up 133.15% YoY) and the FY2025 annual result came in at $107.8 million, up 77.54% from the prior year.
• Total Liabilities improved to $122.4 million in Q1 2026 per DFTX's latest filing, from $107.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $122.4 million in Q1 2026 and bottomed at $9.8 million in Q2 2022.
• The 5-year median for Total Liabilities is $52.5 million (2025), against an average of $56.1 million.
• The widest annual swing landed in 2022, when Total Liabilities tumbled 44.05%; it then surged 269.52% in 2023.
• Tracing DFTX's Total Liabilities over 5 years: stood at $19.1 million in 2022, then jumped by 143.27% to $46.4 million in 2023, then surged by 30.81% to $60.7 million in 2024, then jumped by 77.54% to $107.8 million in 2025, then grew by 13.61% to $122.4 million in 2026.
• Per Business Quant, the three latest DFTX Total Liabilities figures stand at $122.4 million (Q1 2026), $107.8 million (Q4 2025), and $106.3 million (Q3 2025).

Peer Comparison